Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Esslingen Am Neckar – page 75

1 006 clinical trials in Esslingen Am Neckar, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Esslingen Am Neckar at a glance
1 006
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 006 trials in Esslingen Am Neckar

Open in trial search

Study of Lurbinectedin and Doxorubicin for First-line Treatment in Patients with Metastatic Leiomyosarcoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Filgrastim
  • Sponsor:Pharma Mar S.A.

Macular oedema+1

Not recruiting

Study on Ranibizumab Injections and Laser Treatment for Macular Edema in Central Retinal Vein Occlusion Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:Justus-Liebig-Universitaet Giessen

Study on the Effects and Safety of Povorcitinib for Adults with Chronic Spontaneous Urticaria

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Study of Belzutifan and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Study on Methotrexate, Tafasitamab, Lenalidomide, and Rituximab for Patients with Primary Central Nervous System Lymphoma Not Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:University Of Cologne

Study of Enfortumab Vedotin and Pembrolizumab for Patients with Advanced or Metastatic Urothelial Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Seagen Inc.

Plasma cell myeloma

Not recruiting

Study of Daratumumab Injection for Patients with High-Risk Smoldering Multiple Myeloma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Janssen Cilag International

Plasma cell myeloma

Not recruiting

Study Comparing Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Patients with Untreated Multiple Myeloma Not Planning Stem Cell Transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Study on Budesonide Tablets for Preventing Esophageal Narrowing in Adults After Cancer Tissue Removal

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:Dr. Falk Pharma GmbH

Myelofibrosis

Not recruiting

Study on the Effectiveness and Safety of Selinexor and Ruxolitinib for Patients with Myelofibrosis Who Have Not Received Prior Treatment

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:Karyopharm Therapeutics Inc.

Study of Zipalertinib with Chemotherapy vs. Chemotherapy Alone for Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Taiho Oncology Inc.

Neoplasm malignant+2

Not recruiting

Study on Larotrectinib for Treating Children with Advanced Solid Tumors with NTRK Fusion

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Larotrectinib Sulfate
  • Sponsor:Bayer AG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Esslingen Am Neckar

What the registry says about research in the country

01 Lung Cancer Research

Extensive studies focusing on non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), evaluating novel treatment combinations and targeted therapies for various disease stages.

  • Advanced and metastatic disease management
  • Post-surgical treatment optimization
  • Combination therapy approaches

Multiple trials investigating immunotherapy combinations and targeted treatments for improved patient outcomes.

02 Breast Cancer Studies

Innovative research targeting hormone receptor-positive and triple-negative breast cancer, exploring new therapeutic strategies and treatment combinations.

  • Early-stage disease management
  • HER2-negative breast cancer
  • Perioperative treatment approaches

Focus on developing personalized treatment strategies and improving survival outcomes.

03 Hematologic Malignancies

Groundbreaking studies in chronic lymphocytic leukemia (CLL) and related blood cancers, evaluating novel drug combinations and treatment duration strategies.

  • Treatment optimization
  • Disease monitoring approaches
  • Targeted therapy combinations

Research aimed at improving treatment responses and patient quality of life.

04 Gastrointestinal Cancers

Research focusing on hepatocellular carcinoma and gastric cancer, investigating innovative combination therapies and surgical approaches.

  • Advanced disease treatment
  • Perioperative therapy
  • Immunotherapy applications

Studies evaluating novel treatment strategies for improved patient outcomes.

05 Gynecologic Oncology

Clinical trials in ovarian cancer and related conditions, studying maintenance therapies and combination treatments for advanced disease.

  • First-line treatment strategies
  • Maintenance therapy optimization
  • Targeted treatment approaches

Focus on improving survival rates and treatment effectiveness.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.